Protein stability towards aggregation represents a potential challenge for the production and administration of pharmaceuticals. In particular, aggregation can compromise the developability and shelf-life of the products, with consequences for yield and safety, respectively. In this work, we discuss two novel approaches for the analysis of the stability of protein formulations: (1) A microfluidic diffusion-sizing platform to analyze protein sizes and interactions at high protein concentration directly in the solution state with minimal perturbation of the sample. The limited dilution of the sample during the analysis and the possibility to characterize properties directly in the solution state make the technique suitable for the analysis of...
Scanning probe microscopy provides a unique window into the morphology, mechanics and structure of p...
Excipients are included within protein biotherapeutic solution formulations to improve colloidal and...
The increasing demands for biopharmaceuticals to treat different diseases have raised concerns about...
Antibody-based therapeutics continue to be a fast growing field in pharmaceutics due to their increa...
Protein aggregation poses significant risks for formulation stability, efficacy and safety in biopha...
The use of proteins as therapeutics is one of the fastest growing sectors of the pharmaceutical indu...
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. High physical stabili...
Protein aggregation is a major obstacle in recombinant protein production as it reduces the yield of...
Biologics are a class of drug products that are produced in part or in its totality from living orga...
Biotherapeutics, especially monoclonal antibodies (mAbs), is one of the fastest growing groups of ph...
The development time of therapeutic monoclonal antibodies (mAbs) has been shortened by formulation p...
Protein particles in biological drugs can significantly impact drug efficacy and carry the risk of a...
Protein biopharmaceuticals are highly successful, but their utility is compromised by their propensi...
Proteins are one of the most abundant biomacromolecules and play important roles in bioactivities wi...
The term protein aggregation is used in pharmaceutical biotechnology literature to describe a collec...
Scanning probe microscopy provides a unique window into the morphology, mechanics and structure of p...
Excipients are included within protein biotherapeutic solution formulations to improve colloidal and...
The increasing demands for biopharmaceuticals to treat different diseases have raised concerns about...
Antibody-based therapeutics continue to be a fast growing field in pharmaceutics due to their increa...
Protein aggregation poses significant risks for formulation stability, efficacy and safety in biopha...
The use of proteins as therapeutics is one of the fastest growing sectors of the pharmaceutical indu...
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. High physical stabili...
Protein aggregation is a major obstacle in recombinant protein production as it reduces the yield of...
Biologics are a class of drug products that are produced in part or in its totality from living orga...
Biotherapeutics, especially monoclonal antibodies (mAbs), is one of the fastest growing groups of ph...
The development time of therapeutic monoclonal antibodies (mAbs) has been shortened by formulation p...
Protein particles in biological drugs can significantly impact drug efficacy and carry the risk of a...
Protein biopharmaceuticals are highly successful, but their utility is compromised by their propensi...
Proteins are one of the most abundant biomacromolecules and play important roles in bioactivities wi...
The term protein aggregation is used in pharmaceutical biotechnology literature to describe a collec...
Scanning probe microscopy provides a unique window into the morphology, mechanics and structure of p...
Excipients are included within protein biotherapeutic solution formulations to improve colloidal and...
The increasing demands for biopharmaceuticals to treat different diseases have raised concerns about...